0001209191-21-015496.txt : 20210301 0001209191-21-015496.hdr.sgml : 20210301 20210301205405 ACCESSION NUMBER: 0001209191-21-015496 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210225 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kwan Pui San CENTRAL INDEX KEY: 0001733642 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 21700793 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-25 0 0001340652 ChemoCentryx, Inc. CCXI 0001733642 Kwan Pui San C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 0 1 0 0 Principal Acctg Officer Common Stock 2021-03-01 4 M 0 1389 10.86 A 4621 D Common Stock 2021-03-01 4 M 0 1125 11.02 A 5746 D Common Stock 2021-03-01 4 M 0 833 9.04 A 6579 D Common Stock 2021-03-01 4 S 0 1530 68.0843 D 5049 D Common Stock 2021-03-01 4 S 0 1817 68.8862 D 3232 D Stock Option (right to buy) 65.87 2021-02-25 4 A 0 16640 A 2031-02-25 Common Stock 16640 16640 D Stock Option (right to buy) 10.86 2021-03-01 4 M 0 1389 D 2028-03-05 Common Stock 1389 13897 D Stock Option (right to buy) 11.02 2021-03-01 4 M 0 1125 D 2029-03-04 Common Stock 1125 24750 D Stock Option (right to buy) 9.04 2021-03-01 4 M 0 833 D 2029-11-01 Common Stock 833 25834 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $67.64 to $68.60 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $68.64 to $69.19 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. The option was granted on February 25, 2021, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2022, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Not applicable. As of March 1, 2021, and prior to this transaction, the exercised options were fully vested. /s/ Susan M. Kanaya, as Attorney-in-Fact 2021-03-01